131 related articles for article (PubMed ID: 11842089)
1. Increased expression of dihydrodiol dehydrogenase induces resistance to cisplatin in human ovarian carcinoma cells.
Deng HB; Parekh HK; Chow KC; Simpkins H
J Biol Chem; 2002 Apr; 277(17):15035-43. PubMed ID: 11842089
[TBL] [Abstract][Full Text] [Related]
2. Dihydrodiol dehydrogenases regulate the generation of reactive oxygen species and the development of cisplatin resistance in human ovarian carcinoma cells.
Chen J; Adikari M; Pallai R; Parekh HK; Simpkins H
Cancer Chemother Pharmacol; 2008 May; 61(6):979-87. PubMed ID: 17661040
[TBL] [Abstract][Full Text] [Related]
3. Ubiquitous induction of resistance to platinum drugs in human ovarian, cervical, germ-cell and lung carcinoma tumor cells overexpressing isoforms 1 and 2 of dihydrodiol dehydrogenase.
Deng HB; Adikari M; Parekh HK; Simpkins H
Cancer Chemother Pharmacol; 2004 Oct; 54(4):301-7. PubMed ID: 15138708
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.
Chen YJ; Yuan CC; Chow KC; Wang PH; Lai CR; Yen MS; Wang LS
Gynecol Oncol; 2005 Apr; 97(1):110-7. PubMed ID: 15790446
[TBL] [Abstract][Full Text] [Related]
5. Influence of the proto-oncogene c-fos on cisplatin sensitivity.
Moorehead RA; Singh G
Biochem Pharmacol; 2000 Feb; 59(4):337-45. PubMed ID: 10644041
[TBL] [Abstract][Full Text] [Related]
6. Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms.
Wu H; Cao Y; Weng D; Xing H; Song X; Zhou J; Xu G; Lu Y; Wang S; Ma D
Cancer Lett; 2008 Nov; 271(2):260-71. PubMed ID: 18657898
[TBL] [Abstract][Full Text] [Related]
7. "Metabolic reprogramming" in ovarian cancer cells resistant to cisplatin.
Montopoli M; Bellanda M; Lonardoni F; Ragazzi E; Dorigo P; Froldi G; Mammi S; Caparrotta L
Curr Cancer Drug Targets; 2011 Feb; 11(2):226-35. PubMed ID: 21158717
[TBL] [Abstract][Full Text] [Related]
8. [Reversal of drug resistance in human ovarian cancer cells by wild-type PTEN gene and its mechanisms].
Wu HJ; Wu HT; Weng DH; Xing H; Lu YP; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):612-6. PubMed ID: 17983517
[TBL] [Abstract][Full Text] [Related]
9. Expression of the cisplatin resistance phenotype in a human ovarian carcinoma cell line segregates with chromosomes 11 and 16.
Mirakhur B; Parekh HK; Simpkins H
Cancer Res; 1996 May; 56(10):2256-62. PubMed ID: 8625294
[TBL] [Abstract][Full Text] [Related]
10. Nucleotide excision repair in the human ovarian carcinoma cell line (2008) and its cisplatin-resistant variant (C13*).
Moorehead RA; Armstrong SG; Rainbow AJ; Singh G
Cancer Chemother Pharmacol; 1996; 38(3):245-53. PubMed ID: 8646799
[TBL] [Abstract][Full Text] [Related]
11. Emergence of p53 mutant cisplatin-resistant ovarian carcinoma cells following drug exposure: spontaneously mutant selection.
Righetti SC; Perego P; Corna E; Pierotti MA; Zunino F
Cell Growth Differ; 1999 Jul; 10(7):473-8. PubMed ID: 10437915
[TBL] [Abstract][Full Text] [Related]
12. Role of the transcription factor Ets-1 in cisplatin resistance.
Wilson LA; Yamamoto H; Singh G
Mol Cancer Ther; 2004 Jul; 3(7):823-32. PubMed ID: 15252143
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10.
Varma RR; Hector SM; Clark K; Greco WR; Hawthorn L; Pendyala L
Oncol Rep; 2005 Oct; 14(4):925-32. PubMed ID: 16142353
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin resistance in human cervical, ovarian and lung cancer cells.
Chen J; Solomides C; Parekh H; Simpkins F; Simpkins H
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1217-27. PubMed ID: 25894720
[TBL] [Abstract][Full Text] [Related]
15. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
Pavan S; Olivero M; Corà D; Di Renzo MF
Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
[TBL] [Abstract][Full Text] [Related]
16. DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.
Delmastro DA; Li J; Vaisman A; Solle M; Chaney SG
Cancer Chemother Pharmacol; 1997; 39(3):245-53. PubMed ID: 8996528
[TBL] [Abstract][Full Text] [Related]
17. Induction of thymidine phosphorylase expression by Taxol does not enhance Furtulon sensitivity in a cisplatin-resistant human ovarian carcinoma cell line.
Hata K; Osaki M; Kanasaki H; Nakayama K; Fujiwaki R; Ito H; Miyazaki K
Anticancer Res; 2003; 23(2B):1525-31. PubMed ID: 12820419
[TBL] [Abstract][Full Text] [Related]
18. Gene expression response to cisplatin treatment in drug-sensitive and drug-resistant ovarian cancer cells.
Li J; Wood WH; Becker KG; Weeraratna AT; Morin PJ
Oncogene; 2007 May; 26(20):2860-72. PubMed ID: 17072341
[TBL] [Abstract][Full Text] [Related]
19. [Gene expression profiling of human ovarian epithelial tumors by digo nucleotide microarray].
Konno R
Hum Cell; 2001 Dec; 14(4):261-6. PubMed ID: 11925926
[TBL] [Abstract][Full Text] [Related]
20. [Comparison of stepwise and pulse induced cisplatin-resistant ovarian cancer cell sublines].
Cheng G; Li Y; Tian F
Zhonghua Zhong Liu Za Zhi; 2001 Jul; 23(4):305-8. PubMed ID: 11783113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
